GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DiaMedica Therapeutics Inc (NAS:DMAC) » Definitions » Cyclically Adjusted PB Ratio

DiaMedica Therapeutics (DiaMedica Therapeutics) Cyclically Adjusted PB Ratio : 3.80 (As of May. 23, 2024)


View and export this data going back to 2007. Start your Free Trial

What is DiaMedica Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-05-23), DiaMedica Therapeutics's current share price is $2.85. DiaMedica Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $0.75. DiaMedica Therapeutics's Cyclically Adjusted PB Ratio for today is 3.80.

The historical rank and industry rank for DiaMedica Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

DMAC' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.01   Med: 2.88   Max: 9.31
Current: 3.77

During the past years, DiaMedica Therapeutics's highest Cyclically Adjusted PB Ratio was 9.31. The lowest was 1.01. And the median was 2.88.

DMAC's Cyclically Adjusted PB Ratio is ranked worse than
73.73% of 651 companies
in the Biotechnology industry
Industry Median: 1.74 vs DMAC: 3.77

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

DiaMedica Therapeutics's adjusted book value per share data for the three months ended in Mar. 2024 was $1.221. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.75 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


DiaMedica Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for DiaMedica Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DiaMedica Therapeutics Cyclically Adjusted PB Ratio Chart

DiaMedica Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.47 12.07 5.52 2.52 4.05

DiaMedica Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.46 6.65 3.76 4.05 3.70

Competitive Comparison of DiaMedica Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, DiaMedica Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DiaMedica Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DiaMedica Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where DiaMedica Therapeutics's Cyclically Adjusted PB Ratio falls into.



DiaMedica Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

DiaMedica Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.85/0.75
=3.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DiaMedica Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, DiaMedica Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.221/131.7762*131.7762
=1.221

Current CPI (Mar. 2024) = 131.7762.

DiaMedica Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.028 100.560 0.037
201409 -0.229 100.428 -0.300
201412 -0.493 99.070 -0.656
201503 -0.405 99.621 -0.536
201506 -0.242 100.684 -0.317
201509 -0.295 100.392 -0.387
201512 -0.300 99.792 -0.396
201603 -0.232 100.470 -0.304
201606 -0.230 101.688 -0.298
201609 0.293 101.861 0.379
201612 0.201 101.863 0.260
201703 0.001 102.862 0.001
201706 0.121 103.349 0.154
201709 -0.005 104.136 -0.006
201712 0.125 104.011 0.158
201803 0.606 105.290 0.758
201806 0.187 106.317 0.232
201809 0.171 106.507 0.212
201812 1.424 105.998 1.770
201903 1.163 107.251 1.429
201906 0.975 108.070 1.189
201909 0.808 108.329 0.983
201912 0.634 108.420 0.771
202003 0.942 108.902 1.140
202006 0.797 108.767 0.966
202009 1.588 109.815 1.906
202012 1.388 109.897 1.664
202103 1.232 111.754 1.453
202106 1.082 114.631 1.244
202109 1.779 115.734 2.026
202112 1.665 117.630 1.865
202203 1.542 121.301 1.675
202206 1.426 125.017 1.503
202209 1.327 125.227 1.396
202212 1.204 125.222 1.267
202303 1.021 127.348 1.057
202306 1.574 128.729 1.611
202309 1.466 129.860 1.488
202312 1.345 129.419 1.369
202403 1.221 131.776 1.221

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


DiaMedica Therapeutics  (NAS:DMAC) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


DiaMedica Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of DiaMedica Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


DiaMedica Therapeutics (DiaMedica Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
301 Carlson Parkway, Suite 210, Minneapolis, MN, USA, 55305
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.
Executives
Jan Stahlberg 10 percent owner C/O TRILL INVEST AB, SVEAVAGEN 17 FL 18, STOCKHOLM V7 SE 111 57
Scott Kellen officer: CFO and Secretary 3405 ANNAPOLIS LANE, SUITE 200, MINNEAPOLIS MN 55447
Randall Michael Giuffre director 2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Ab Trill 10 percent owner SVEAVAGEN 17, 18TH FLOOR, STOCKHOLM V7 SE-11157
Richard D. Pilnik director 2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Dietrich John Pauls director, officer: President and CEO 2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Richard Ii Jacinto 10 percent owner 394 SADDLE BACK TRAIL, FRANKLIN LAKES NJ 07417
David J. Wambeke officer: Chief Business Officer 301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS MN 55305
Private Ab Tomeqt 10 percent owner C/O KINKON AB, BIBLIOTEKSGATAN 25, STOCKHOLM V8 11435
Koch Thomas Von 10 percent owner TOMENTERPRISE AB, BOX 5322, STOCKHOLM V7 102 47
Ab Tomenterprise 10 percent owner C/O EQT PARTNERS AB, BOX 16509, STOCKHOLM V7 103 27
Charles Pauling Semba director TWO CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Richard Kuntz director MEDTRONIC, INC., 710 MEDTRONIC PWKY MS LC 310, MINNEAPOLIS MN 55432
Tanya Lewis director C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVE., NEWTON MA 02459
Julie Vanorsdel Daves officer: SVP Clinical Development Oper. 301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS MN 55305